Catalyst Event

Moderna Inc (MRNA) · Other

From Akros U.S. Large Cap 500 Protective Allocation Monthly Index (A500PAM)

8/5/2026, 12:00:00 AM

OtherSentiment: Positive

The U.S. FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of August 5, 2026, for a decision on Moderna's seasonal flu vaccine, mRNA-1010; a regulatory decision on a key pipeline product is a high-impact catalyst likely to cause ≥10% price impact, scheduled.

Korean Translation

2026년 8월 5일 FDA가 독감 백신(mRNA-1010) 승인 여부를 결정할 예정임. 주요 제품의 규제 승인 결정은 10% 이상의 주가 영향이 예상됨.

Related Recent Events

View Full Timeline